Eurizon Capital SGR S.p.A. trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 23.5% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,838 shares of the biotechnology company’s stock after selling 1,178 shares during the period. Eurizon Capital SGR S.p.A.’s holdings in United Therapeutics were worth $2,053,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Maryland State Retirement & Pension System raised its stake in United Therapeutics by 10.0% during the third quarter. Maryland State Retirement & Pension System now owns 2,407 shares of the biotechnology company’s stock valued at $1,304,000 after buying an additional 218 shares in the last quarter. Ritholtz Wealth Management grew its position in shares of United Therapeutics by 33.1% in the 3rd quarter. Ritholtz Wealth Management now owns 2,536 shares of the biotechnology company’s stock worth $1,374,000 after acquiring an additional 631 shares in the last quarter. Jefferies Financial Group Inc. grew its position in shares of United Therapeutics by 4.2% in the 3rd quarter. Jefferies Financial Group Inc. now owns 6,975 shares of the biotechnology company’s stock worth $3,780,000 after acquiring an additional 278 shares in the last quarter. Machina Capital S.A.S. grew its position in shares of United Therapeutics by 288.1% in the 3rd quarter. Machina Capital S.A.S. now owns 3,524 shares of the biotechnology company’s stock worth $1,910,000 after acquiring an additional 2,616 shares in the last quarter. Finally, Illinois Municipal Retirement Fund increased its holdings in shares of United Therapeutics by 2.5% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 40,014 shares of the biotechnology company’s stock valued at $21,683,000 after acquiring an additional 972 shares during the last quarter. 94.08% of the stock is owned by institutional investors.
United Therapeutics Stock Performance
United Therapeutics stock opened at $587.88 on Tuesday. United Therapeutics Corporation has a one year low of $455.63 and a one year high of $614.23. The company has a 50-day simple moving average of $544.61 and a 200-day simple moving average of $536.98. The firm has a market capitalization of $25.04 billion, a P/E ratio of 22.18, a P/E/G ratio of 3.94 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). The firm had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $7.16 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 25.08 earnings per share for the current year.
United Therapeutics announced that its Board of Directors has authorized a share repurchase program on Thursday, October 22nd that authorizes the company to repurchase $2 billion in shares. This repurchase authorization authorizes the biotechnology company to buy up to 8.3% of its stock through open market purchases. Share repurchase programs are often an indication that the company’s board believes its stock is undervalued.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on UTHR shares. Leerink Partners boosted their price target on United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a report on Monday, October 19th. TD Cowen raised their price objective on United Therapeutics from $675.00 to $700.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. UBS Group set a $725.00 price objective on shares of United Therapeutics in a report on Monday, October 19th. Morgan Stanley boosted their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. Finally, Weiss Ratings lowered shares of United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $676.40.
Check Out Our Latest Stock Report on UTHR
Insider Activity at United Therapeutics
In other news, Director Christopher Patusky sold 1,210 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $580.00, for a total value of $701,800.00. Following the completion of the transaction, the director owned 2,140 shares of the company’s stock, valued at approximately $1,241,200. This represents a 36.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Friday, November 13th. The shares were sold at an average price of $592.42, for a total value of $5,627,990.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $192,206,522.06. This trade represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 412,238 shares of company stock worth $221,790,391 in the last three months. 8.60% of the stock is owned by company insiders.
United Therapeutics Profile
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Further Reading
- Five stocks we like better than United Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
